## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($94.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Incyte Board Exit Closes an Era for the Biotech’s Longtime Leader**
- Source: MyChesCo | 20251223T110216 | Somewhat-Bullish | Relevance: 100%
- Hervé Hoppenot has resigned from Incyte's board of directors, formally ending his transition period after a long tenure as the company's chairman and CEO. His departure marks a clean break as Incyte moves into its next phase of growth, with Julian Baker of Baker Bros. Advisors LP acknowledging Hoppenot's instrumental role in transforming the company into a major biotech force. Incyte, headquartered in Wilmington, DE, is known for discovering, developing, and commercializing proprietary therapeutics in oncology and inflammation.

**2. Incyte (INCY) Valuation Check After Japan Oncology Approvals for Minjuvi and Zynyz**
- Source: Simply Wall Street | 20251223T084310 | Somewhat-Bullish | Relevance: 100%
- Incyte (INCY) has seen its share price climb to $100.71 after receiving back-to-back oncology approvals in Japan for its cancer drugs Minjuvi and Zynyz, expanding its international presence. The stock is currently deemed "almost exactly priced" for its next phase of growth, with a fair value estimate of $99.62, though some models suggest it might still be undervalued compared to industry averages. Investors are advised to consider the company's growth profile, potential risks to its key drugs, and specific profitability targets.

**3. Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma**
- Source: PharmiWeb.com | 20251222T110836 | Bullish | Relevance: 100%
- Incyte Biosciences Japan G.K. has received approval from Japan's MHLW for Minjuvi® (tafasitamab) combined with rituximab and lenalidomide to treat relapsed or refractory follicular lymphoma (2L+ FL) in adults. This marks the first dual-targeted CD19 and CD20 immunotherapy combination for this condition in Japan, offering a chemotherapy-free option based on the pivotal Phase 3 inMIND trial which showed improved progression-free survival. The approval addresses a significant unmet need for additional treatment options for this incurable form of B-cell non-Hodgkin lymphoma.

**4. New lymphoma drug combo in Japan keeps cancer from progressing longer**
- Source: Stock Titan | 20251222T074643 | Bullish | Relevance: 100%
- Incyte Japan has received approval from Japan's MHLW for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (FL). This dual-targeted CD19 and CD20 immunotherapy combination significantly improved progression-free survival in the Phase 3 inMIND trial, offering a chemotherapy-free option. Follicular lymphoma is a common, incurable form of non-Hodgkin lymphoma in Japan, and this approval addresses a significant unmet need.

**5. How Incyte Corporation (INCY) Affects Rotational Strategy Timing**
- Source: Stock Traders Daily | 20251221T060757 | Neutral | Relevance: 100%
- An analysis of Incyte Corporation (INCY) indicates a mid-channel oscillation pattern with positive near-term sentiment potentially eroding a mid-term weak bias within a long-term strength context. The article details specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. It highlights an exceptional risk-reward short setup targeting an 11.4% downside with 0.3% risk.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.05M) |
| Sells | 20 ($25.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $26M sold (20 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Forward P/E 13.1x attractive for 14% earnings growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($25.8M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.8B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 13.1 |
| Current P/E | 15.0 |
| YoY Growth | 14.4% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 3.0% to 1.5% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 (-0.5%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 54. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.47% (CS: 88) | Neutral |
| RSI_14 | 53.7 | Neutral |
| MACD Histogram | 0.13 | Bullish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.025x | Above |
| vs SMA200 | 1.292x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $100.91
- **Stop Loss:** $94.47 (6.4% risk)
- **Target:** $107.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 186
- **Position Value:** $18,769.26
- **Portfolio %:** 18.77%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*